Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease　― Japanese Guideline on the Management of Asymptomatic Hyperuricemia ―

Hisatome, Ichiro; Li, Peili; Miake, Junichiro; Taufiq, Fikri; Mahati, Endang; Maharani, Nani; Utami, Sulistiyati Bayu; Kuwabara, Masanari; Bahrudin, Udin; Ninomiya, Haruaki

doi:10.1253/circj.cj-20-0406

Cited by 74 publications

(50 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We also found that our data were also higher than Japan 1%-3%, 28 which might due to the early antiurate therapy to asymptomatic patients, and their high cut-off of HUA (7.0 mg/ dL in both sex). 29 Notably, there was a lack of agreement on cut-off value of HUA. Previously, HUA was defined with the classic cut-off (>7.0 mg/dL in men and >6.0 mg/dL in women), but recent evidences suggested that a lower level should be considered as a more appreciate cut-off when addressing its negative impact on cardiovascular system (5.6 mg/dL for both sex).…”

Section: Discussionmentioning

confidence: 99%

“…7 11 However, 2020 American College of Rheumatology Guideline for the Management of Gout Guidelines and Japanese Guideline on Management of Hyperuricemia and Gout third edition suggested that the normal upper limit is 6.8 mg/dL, and anything over 7 mg/dL (for both sex) is considered saturated, and symptoms can occur. 29 We did the addition analysis for the prevalence and related factors analysis of HUA based on the new cut-off (>7.0 mg/dL) (online supplemental table 1 and online supplemental figure 1). The prevalence rates of HUA (>7.0 mg/dL) of total subjects were 3.65% (95% CI 3.30% to 3.98%).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence and related factors of hyperuricaemia in Shanghai adult women of different ages: a multicentre and cross-sectional study

Tao

et al. 2021

BMJ Open

View full text Add to dashboard Cite

ObjectiveWomen in different age phases have different metabolism and hormone levels that influence the production and excretion of uric acid. We aimed to investigate the prevalence and related factors of hyperuricaemia among women in various age phases.Study designObservational, cross-sectional study.SettingData were obtained from women at three health check-up centres in Shanghai.ParticipantsAdult women from three health check-up centres were recruited. Exclusion criteria were individuals with pregnancy, cancer, incomplete information. Finally, 11 601 participants were enrolled.ResultsThe prevalence rates of hyperuricaemia of total subjects were 11.15% (95% CIs 10.57% to 11.72%). The prevalence of hyperuricaemia in 18–29, 30–39, 40–49, 50–59, 60–69 and ≥70 years old was 6.41% (95% CI 4.97% to 7.86%), 5.63% (4.71% to 6.55%), 6.02% (5.01%% to 7.03%), 11.51% (10.19% to 12.82%), 16.49% (15.03% to 17.95%) and 23.98% (21.56% to 26.40%), respectively. Compared with 18–29 years old, the ORs for hyperuricaemia in other age phases were 0.870 (95% CI 0.647 to 1.170, p=0.357), 0.935 (0.693 to 1.261, p=0.659), 1.898 (1.444 to 2.493, p<0.001), 2.882 (2.216 to 3.748, p<0.001) and 4.602 (3.497 to 6.056, p<0.001), respectively. During the 18–29 years old, the related factors for hyperuricaemia were obesity and dyslipidaemia. During the 30–59 years old, the related factors were obesity, dyslipidaemia, hypertension and chronic kidney disease (CKD). Over the 60 years old, the occurrence of hyperuricaemia was mainly affected by obesity, dyslipidaemia and CKD, while hypertension cannot be an impact factor for hyperuricaemia independently of obesity and dyslipidaemia.ConclusionAfter 50 years old, the prevalence of hyperuricaemia in Shanghai women has increased significantly and reaches the peak after 70. Obesity and dyslipidaemia are two main related factors for hyperuricaemia during all ages, while diabetes mellitus and nephrolithiasis have no relationship with hyperuricaemia throughout. CKD is an independent impact factor for hyperuricaemia after 30 years old.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Prevalence and related factors of hyperuricaemia in Shanghai adult women of different ages: a multicentre and cross-sectional study

Tao

et al. 2021

BMJ Open

View full text Add to dashboard Cite

show abstract

“…HbA HbA 1c 1c risk of nephrolithiasis. 24 While it is indicated that reduced serum uric acid may contribute to reduced renal and cardiovascular risks, [25][26][27] further studies are needed to determine whether the lowering effect on serum uric acid by SGLT2 inhibitors contributes to the risk reduction. Nonetheless, the present analysis had a few limitations.…”

Section: Hba Hba 1c 1cmentioning

confidence: 99%

Factors Influencing Change in Serum Uric Acid After Administration of the Sodium‐Glucose Cotransporter 2 Inhibitor Luseogliflozin in Patients With Type 2 Diabetes Mellitus

Chino

Kuwabara

Hisatome

2021

The Journal of Clinical Pharma

Self Cite

View full text Add to dashboard Cite

Although sodium-glucose cotransporter 2 (SGLT2) inhibitors lower serum uric acid, their long-term effect on uric acid metabolism is not well understood. We analyzed pooled data from studies wherein patients with type 2 diabetes mellitus received luseogliflozin, an SGLT2 inhibitor. Upon stratifying patients by baseline glycated hemoglobin (HbA 1c ) or serum uric acid, lower HbA 1c or higher serum uric acid level was associated with a greater reduction in serum uric acid after treatment. At week 12 of treatment, significant increases in urinary glucose/creatinine (Cr) ratio and urinary uric acid clearance/Cr clearance ratio (C UA /C Cr ratio) and a significant reduction in serum uric acid were observed. Comparison of the subgroups of patients with a reduction or an increase in serum uric acid showed that the increase subgroup had a higher estimated glomerular filtration rate (eGFR) at baseline, and the eGFR was significantly reduced, associated with a significant reduction in the C UA /C Cr ratio. Multiple regression analysis showed that the reduction in serum uric acid in the luseogliflozin group was strongly associated with baseline high serum uric acid, low HbA 1c levels, and an increase in eGFR. Luseogliflozin was shown to reduce serum uric acid by enhancing urinary uric acid excretion in association with increased urinary glucose. Treatment with luseogliflozin resulted in increased serum uric acid in some patients, which may be due to reduced glomerular filtration of uric acid via the tubuloglomerular feedback. SGLT2 inhibitors reduced serum uric acid desirably in patients with type 2 diabetes mellitus with low HbA 1c and high serum uric acid.

show abstract

“…Незважаючи на публікації даних сотень випробувань щодо ХХН, гіперурикемії і подагри, лікування цих станів залишається неоптимальним [28][29][30][31]. Нами було розглянуто останні версії рекомендацій з клінічної практики, що були розроблені групами ревматології і суміжних спеціальностей [32][33][34][35][36][37][38][39][40]. Рекомендації узгоджувались із цільовим рівнем СК у сироватці крові для тривалого контролю щодо деяких показань для зниження рівня уратів, препаратів пер-Vol.…”

Section: тема номера / Cover Storyunclassified

Технологии Сохранения Функции Почек У Пациентов С Хронической Болезнью Почек И Гиперурикемией

Ivanov¹,

Бевзенко²,

Kushnirenko³

et al. 2021

KIDNEYS

View full text Add to dashboard Cite

The prevalence of chronic kidney disease (CKD) and hyperuricemia is increasing globally. The steady increase in the number of patients with impaired renal function associated with diabetes mellitus, arterial hypertension, and an increase in life expectancy ultimately leads to significant costs associated with the need to use expensive methods of renal replacement therapy. The main task for physicians is the timely determination and slowing down of the progression of CKD, and renoprotection. Hyperuricemia is considered an independent risk factor for the onset and progression of the disease, in addition to the traditional microalbuminuria and decreased glomerular filtration rate. The urgency of detecting hyperuricemia is due to the possibility of its further correction to improve the prognosis of the disease and delay the end stage of CKD, improve the quality of life and reduce the cost of treatment of patients. A decrease in the total pool of uric acid in the body helps to minimize the risk of arthropathy and nephrolithiasis, exacerbation of gout, progression of renal failure and other complications. However, despite hundreds of published clinical studies on the diagnosis and treatment of patients with CKD, the quality of care remains suboptimal. The article presents versatile technologies of preserving renal function in patients with CKD and hyperuricemia, which require improvement.

show abstract

Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease　― Japanese Guideline on the Management of Asymptomatic Hyperuricemia ―

Cited by 74 publications

References 73 publications

Prevalence and related factors of hyperuricaemia in Shanghai adult women of different ages: a multicentre and cross-sectional study

Prevalence and related factors of hyperuricaemia in Shanghai adult women of different ages: a multicentre and cross-sectional study

Factors Influencing Change in Serum Uric Acid After Administration of the Sodium‐Glucose Cotransporter 2 Inhibitor Luseogliflozin in Patients With Type 2 Diabetes Mellitus

Технологии Сохранения Функции Почек У Пациентов С Хронической Болезнью Почек И Гиперурикемией

Contact Info

Product

Resources

About

Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease ― Japanese Guideline on the Management of Asymptomatic Hyperuricemia ―

Cited by 74 publications

References 73 publications

Prevalence and related factors of hyperuricaemia in Shanghai adult women of different ages: a multicentre and cross-sectional study

Prevalence and related factors of hyperuricaemia in Shanghai adult women of different ages: a multicentre and cross-sectional study

Factors Influencing Change in Serum Uric Acid After Administration of the Sodium‐Glucose Cotransporter 2 Inhibitor Luseogliflozin in Patients With Type 2 Diabetes Mellitus

Технологии Сохранения Функции Почек У Пациентов С Хронической Болезнью Почек И Гиперурикемией

Contact Info

Product

Resources

About

Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease　― Japanese Guideline on the Management of Asymptomatic Hyperuricemia ―